Cervical Cancer – Pipeline Review, H2 2017 – Research and Markets

Cancer – Pipeline Review, H2 2017”
report has been added to Research
and Markets’

Cervical Cancer – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Cervical Cancer
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Cervical Cancer and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Phase III,
Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6,
34, 36, 47, 9 and 4 respectively. Similarly, the Universities portfolio
in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 4,
11 and 6 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Cervical Cancer – Overview
  3. Cervical Cancer – Therapeutics Development
  4. Cervical Cancer – Therapeutics Assessment
  5. Cervical Cancer – Companies Involved in Therapeutics Development
  6. Cervical Cancer – Drug Profiles
  7. Cervical Cancer – Dormant Projects
  8. Cervical Cancer – Discontinued Products
  9. Cervical Cancer – Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/9whldc/cervical_cancer?w=4


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Cervical
Cancer Drugs